Opening book details…
Can I read Crossover to Photodynamic Therapy or Micropulse Laser After Failure of Primary Treatment of Chronic Central Serous Chorioretinopathy: The REPLACE Trial on EtoBox?
Crossover to Photodynamic Therapy or Micropulse Laser After Failure of Primary Treatment of Chronic Central Serous Chorioretinopathy: The REPLACE Trial by Thomas J. van Rijssen; Elon H.C. van Dijk; Paula Scholz; Myrte B. Breukink; Greet Dijkman; Petrus J.H. Peters; Roula Tsonaka; Robert E. MacLaren; Susan M. Downes; Sascha Fauser; Camiel J.F. Boon; Carel B. Hoyng is a Medicine article available to read on EtoBox.
What is Crossover to Photodynamic Therapy or Micropulse Laser After Failure of Primary Treatment of Chronic Central Serous Chorioretinopathy: The REPLACE Trial about?
## Purpose: To assess whether chronic central serous chorioretinopathy (ccsc) patients without a complete resolution of subretinal fluid (srf) after either half-dose photodynamic therapy (pdt) or high-density subthreshold micropulse laser (hsml) treatment may benefit from crossover treatment. ## Design: Multicenter prospective interventional case series. ## Methods: Ccsc patients with persistent srf at the final visit of the place trial were included. patients received crossover treatment with either half-dose pdt or hsml. ## Results: Thirty-two patients received pdt and 10 patients received hsml. at the first evaluation visit (6-8 weeks after treatment), 81% of patients in the pdt group had complete resolution of srf, while none of the hsml-treated patients had complete resolution of srf. at final visit (1 year after baseline), 78% (p = .030) and 67% (p = .109) of the patients, respectively, had a complete resolution of srf. the mean retinal sensitivity in the pdt group increased from 21.7 db (standard error [se]: 0.9) to 23.4 db (se: 0.8) at evaluation visit 1 (p = .003), to 24.7db (se: 0.8) at final visit (p < .001), while there were no significant changes in the hsml group (23.
Who reads Crossover to Photodynamic Therapy or Micropulse Laser After Failure of Primary Treatment of Chronic Central Serous Chorioretinopathy: The REPLACE Trial?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Thomas J. van Rijssen; Elon H.C. van Dijk; Paula Scholz; Myrte B. Breukink; Greet Dijkman; Petrus J.H. Peters; Roula Tsonaka; Robert E. MacLaren; Susan M. Downes; Sascha Fauser; Camiel J.F. Boon; Carel B. Hoyng
- Publisher
- Elsevier Science; Elsevier ; Elsevier BV (ISSN 0002-9394)
- Published
- 2020
- Language
- EN
- Field
- Medicine (Health Sciences)